Literature DB >> 31930093

Progress in the treatment of infantile hemangioma.

Zhao-Yang Chen1, Qing-Nan Wang1, Yang-Hui Zhu1, Ling-Yan Zhou1, Ting Xu1, Zhi-Yao He1, Yang Yang1.   

Abstract

Infantile hemangioma (IH) is a common benign tumor, which mostly resolves spontaneously; however, children with high-risk IH need treatment. Currently, the recognized first-line treatment regimen for IH is oral propranolol, but research on the pathogenesis of IH has led to the identification of new therapeutic targets, which have shown good curative effects, providing more options for disease treatment. This article summarizes the applications of different medications, dosages, and routes of administration for the treatment of IH. In addition to drug therapy, this article also reviews current therapeutic options for IH such as laser therapy, surgical treatment, and observation. To provide the best treatment, therapeutic regimens for IH should be selected based on the child's age, the size and location of the lesion, the presence of complications, the implementation conditions, and the potential outcomes of the treatment. 2019 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Infantile hemangioma (IH); beta blocker; laser; medication; surgery

Year:  2019        PMID: 31930093      PMCID: PMC6944559          DOI: 10.21037/atm.2019.10.47

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  10 in total

1.  Timing and Efficacy of 595-nm Pulsed-Dye Laser Combined with 0.5% Timolol Maleate Solution in the Treatment of Superficial Infantile Hemangiomas.

Authors:  Weikang Shi; Huiyi He; Jicong Jiang; Yu Gao; Hehe Quan
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-11-02

2.  Treatments for infantile Hemangioma: A systematic review and network meta-analysis.

Authors:  Qiang Fei; Yu Lin; Xian Chen
Journal:  EClinicalMedicine       Date:  2020-08-18

3.  Efficacy of Combined Topical Timolol and Oral Propranolol for Treating Infantile Hemangioma: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Junbo Qiao; Junjie Lin; Dexin Zhang; Junhua Li; Changkuan Chen; Hongye Yu; Xiaodi Li; Bin Fang
Journal:  Front Pharmacol       Date:  2020-10-08       Impact factor: 5.810

4.  Propranolol inhibits infantile hemangioma by regulating the miR-424/vascular endothelial growth factor-A (VEGFA) axis.

Authors:  Zhen-Bo Wu; Sen-Lin Shi; Feng-Jun Pan; Li Li; Hong-Yu Chen
Journal:  Transl Pediatr       Date:  2021-07

5.  Long non-coding RNA breast cancer-associated transcript 54 sponges microRNA-1269b to suppress the proliferation of hemangioma-derived endothelial cells.

Authors:  Zhonjun Lv; Ke Yang; Ya Wang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

6.  Integrated WGCNA and PPI Network to Screen Hub Genes Signatures for Infantile Hemangioma.

Authors:  Miao Xu; Tianxiang Ouyang; Kaiyang Lv; Xiaorong Ma
Journal:  Front Genet       Date:  2021-01-15       Impact factor: 4.599

7.  Development and validation of psychological status questionnaire for parents of infantile hemangiomas.

Authors:  Wei Peng; Haijin Liu; Jincai Chen; Yanan Zheng; Xianyun Xu; Hong Tang; Qian Liu
Journal:  Transl Pediatr       Date:  2021-12

8.  Treatment patterns and outcomes in children with infantile hemangiomas: A retrospective observational analysis.

Authors:  Yantao Cai; Ying Ge; Carolina Oi Lam Ung; Fuli Li; Jiaqi Wang; Chenglai Xia; Hao Hu
Journal:  SAGE Open Med       Date:  2021-11-23

9.  Propranolol vs. steroids in the treatment of infantile hemangiomas: A meta-analysis.

Authors:  Yiting You; Yadong Li; Yiting Xiao; Jinsong Zhang
Journal:  Mol Clin Oncol       Date:  2021-06-10

10.  LncRNA-TUG1 promotes the progression of infantile hemangioma by regulating miR-137/IGFBP5 axis.

Authors:  Lili Zhou; Xiao Jia; Xiangzheng Yang
Journal:  Hum Genomics       Date:  2021-08-06       Impact factor: 4.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.